Day two, Thursday, 22 March 2012

Day one, Wednesday, 21 March 2012 ›

Day two, Thursday, 22 March 2012 ›

last modified: 16 March '12

Please enable javascript to see more information on speakers

8am

Registration and coffee

8.45am

Opening remarks from the chair

9am

Get over it: embrace payer expectations by introducing them early in product development

Dr Raf De Wilde

Raf De Wilde, PhD, is an expert in global pricing and market access. He recently accepted the role of Associate Vice President for UBC Global Market Access Consulting, after a career of over 30 years in Johnson & Johnson. Dr. De Wilde introduced...

more..

It does not make sense to start a development program that will not answer the current and to be expected questions from payers
Key decisions that will make or break market access for a new product are taken very early during development
Payer expectations also offer opportunities, playing into these
opportunities better than competition can make the difference later in the market
Special attention will be given to expectations regarding biomarkers, real-world efficacy and comparative effectiveness

› Dr Raf De Wilde, Associate Vice President, Global Market Access Consulting, UBC

9.30am

Case study: Launching and selling a pharmaceutical compound with the payer in mind

Stefan Walzer

Stefan Walzer has 8 years experience in payer strategy and its implementation and is currently General Manager of Assessment in Medicine (located in Germany). He has been working as a payer consultant for various global pharmaceutical and medical...

more..

Taking the needs and requests of payers across the world into account when developing a product
Preparing and executing a communication strategy or payers
Successfully developing a consistent payer and pricing strategy

› Stefan Walzer, General Manager, AiM Assessment in Medicine

9.55am

Panel discussion: How can payers and industry work together to ensure that innovative and valuable treatments make it to the market?

Dr Raf De Wilde

more..

Dr Martin van der Graaff

Dr Graaff spent 4 years in administration form development in Organon, and 7 years in pharmacokinetics and preclinical development at Solvay. He then made the switch from R&D to policy development and moved to Nefarma, the Dutch Association of the...

more..

Stefan Walzer

more..

Where do we agree and where do we differ?
How big is the gulf and can it be closed?
Putting patients at the centre of the decision making process

10.25am

Morning coffee

10.55am

Learning from best (& worst) practice: pioneering new ways to make Market Access work for healthcare companies

Colin Wight

Colin Wight, Chief Executive, founded GalbraithWight Ltd 15 years ago in January 1997. Dedicated 100% to healthcare, GalbraithWight specialises in global healthcare Consultancy including market access & commercial excellence, and Learning &...

more..

The good news - what's working well
The bad news - barriers, hurdles & obstacles to operational success
Pioneering new ways to make market access work across the company from a global, region & country perspective

› Colin Wight, CEO, GalbraithWight

11.25am

Changing beacons: Navigating the Dutch reimbursement system after 2012 beacons

Dr Martin van der Graaff

more..

Conditional reimbursement
What is an add-on?
What about results of outcomes research?
Modernizing the reimbursement system
Some cases: enthralling or appalling?

› Dr Martin van der Graaff, Secretary, Reimbursement Committee, CVZ

11.55am

Russia

Dr Maria Avxentyeva

Avxentyeva Maria, Doctor of Medical Sciences, vice-director of the Research Institute of Clinical and Economical Expertise at Russian State Medical University, professor at the Chair of Public Health and Preventive Medicine at Moscow medical academy ...

more..

Russian health care system: key points
Introduction of pricing regulation
Russian reimbursement system – what can be expected?

› Dr Maria Avxentyeva, Head of the Research Department of Standardization, Licensing and Accreditation, Moscow Medical Academy

12.20pm

Lunch

1.20pm

Market access for orphan drugs

Dr Anna Bucsics

Anna Bucsics was born in Budapest, Hungary and lives in Austria. She received her medical degree from the Karl-Franzens-University of Graz, Austria, where she did postgraudate research work in neuro¬pharma¬cology at the Department of Experimental...

more..

Current reimbursement status for orphan drugs
What kind of evidence is needed to support claims?
How can access be improved for orphan treatments?

› Dr Anna Bucsics, Dept Head, Main Association of Austrian Social Security Institutions

Asia Focus

1.45pm

Latest Changes to the P&R Processes in Japan

Donald Macarthur

Donald Macarthur is an independent analyst, consultant and writer on the pharmaceutical business environment across Europe and parts of Asia. He publishes his own reports at justpharmareports.com and trades as DM Pharma Issues Ltd as a...

more..

› Donald Macarthur, Principal, DM Pharma Issues & Justpharmareports

2.10pm

Taiwan

Dr Grace Wu

Dr. Wu obtained her PhD from Institute of Epidemiology, College of Public Health, National Taiwan University: and the subject of her dissertation was the applications of multi-state model to cancer screening using examples from breast cancer...

more..

Healthcare in Taiwan - compulsory national health insurance and National Health Insurance (NHI)
Rules of pricing and reimbursement and its relationship with HTA assessments
Future planning for second-generation NHI Act

› Dr Grace Wu, Researcher, Division of Health Technology Assessment, Center for Drug Evaluation, Taiwan.

2.35pm

South Korea

Sang Moo Lee

Sang Moo Lee MD, PhD is Executive director of Center for New Health Technology Assessment in NECA (National Evidence-based healthcare Collaborating Agency). His background is a clinician, and his major is internal medicine, and his sub-specialty is...

more..

Overview of the programme to establish universal healthcare insurance coverage and the impact on pharmaceutical market access
Dealing with uncertainty
Conclusions